Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56


CRISPR-engineered T cells in patients with refractory cancer.

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH.

Science. 2020 Feb 6. pii: eaba7365. doi: 10.1126/science.aba7365. [Epub ahead of print]


Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.

Linette GP, Becker-Hapak M, Skidmore ZL, Baroja ML, Xu C, Hundal J, Spencer DH, Fu W, Cummins C, Robnett M, Kaabinejadian S, Hildebrand WH, Magrini V, Demeter R, Krupnick AS, Griffith OL, Griffith M, Mardis ER, Carreno BM.

Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23662-23670. doi: 10.1073/pnas.1906026116. Epub 2019 Nov 4.


Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.

Linette GP, Carreno BM.

Curr Hematol Malig Rep. 2019 Aug;14(4):286-291. doi: 10.1007/s11899-019-00523-x. Review.


Heating up cancer vaccines.

Ghassemi S, Carreno BM.

Sci Immunol. 2017 Nov 10;2(17). pii: eaap9419. doi: 10.1126/sciimmunol.aap9419.


Neoantigen Vaccines Pass the Immunogenicity Test.

Linette GP, Carreno BM.

Trends Mol Med. 2017 Oct;23(10):869-871. doi: 10.1016/j.molmed.2017.08.007. Epub 2017 Aug 31.


Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.

Ghasemi R, Lazear E, Wang X, Arefanian S, Zheleznyak A, Carreno BM, Higashikubo R, Gelman AE, Kreisel D, Fremont DH, Krupnick AS.

Nat Commun. 2016 Sep 21;7:12878. doi: 10.1038/ncomms12878.


A Vaccine for Cancer?

Carreno BM, Mardis ER.

Sci Am. 2016 Apr;314(4):46. doi: 10.1038/scientificamerican0416-46. No abstract available.


pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens.

Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M.

Genome Med. 2016 Jan 29;8(1):11. doi: 10.1186/s13073-016-0264-5.


Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP.

Science. 2015 May 15;348(6236):803-8. doi: 10.1126/science.aaa3828. Epub 2015 Apr 2.


Dendritic cell-based vaccines: Shining the spotlight on signal 3.

Linette GP, Carreno BM.

Oncoimmunology. 2013 Nov 1;2(11):e26512. Epub 2013 Oct 10.


IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP.

J Clin Invest. 2013 Aug;123(8):3383-94. doi: 10.1172/JCI68395. Epub 2013 Jul 11.


Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH.

Blood. 2013 Aug 8;122(6):863-71. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14.


Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer.

Kreisel D, Gelman AE, Higashikubo R, Lin X, Vikis HG, White JM, Toth KA, Deshpande C, Carreno BM, You M, Taffner SM, Yokoyama WM, Bui JD, Schreiber RD, Krupnick AS.

Cancer Res. 2012 Sep 1;72(17):4311-7. Epub 2012 Jun 29.


Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells.

Carreno BM, Becker-Hapak M, Chan M, Lie WR, Wang X, Hansen TH, Linette GP.

J Immunol. 2012 Jun 15;188(12):5839-49. doi: 10.4049/jimmunol.1103647. Epub 2012 May 9.


Cancer genome sequencing and its implications for personalized cancer vaccines.

Li L, Goedegebuure P, Mardis ER, Ellis MJ, Zhang X, Herndon JM, Fleming TP, Carreno BM, Hansen TH, Gillanders WE.

Cancers (Basel). 2011 Nov 25;3(4):4191-211. doi: 10.3390/cancers3044191.


Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.

Carreno BM, Garbow JR, Kolar GR, Jackson EN, Engelbach JA, Becker-Hapak M, Carayannopoulos LN, Piwnica-Worms D, Linette GP.

Clin Cancer Res. 2009 May 15;15(10):3277-86. doi: 10.1158/1078-0432.CCR-08-2502. Epub 2009 May 15.


CD40 regulates human dendritic cell-derived IL-7 production that, in turn, contributes to CD8(+) T-cell antigen-specific expansion.

Carreno BM, Becker-Hapak M, Linette GP.

Immunol Cell Biol. 2009 Feb;87(2):167-77. doi: 10.1038/icb.2008.80. Epub 2008 Nov 11.


The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex.

Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, Tomkinson KN, Fitz LJ, Wolfman NM, Collins M, Dunussi-Joannopoulos K, Chatterjee-Kishore M, Carreno BM.

J Immunol. 2008 Aug 15;181(4):2799-805.


Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides.

Truscott SM, Wang X, Lybarger L, Biddison WE, McBerry C, Martinko JM, Connolly JM, Linette GP, Fremont DH, Hansen TH, Carreno BM.

J Biol Chem. 2008 Mar 21;283(12):7480-90. doi: 10.1074/jbc.M709935200. Epub 2008 Jan 14.


Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells.

Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, Ross JF, Qiu Y, Whitters MJ, Tomkinson KN, Dunussi-Joannopoulos K, Carreno BM, Collins M, Wolfman NM.

J Biol Chem. 2007 May 4;282(18):13447-55. Epub 2007 Mar 13.


PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.

Carter LL, Leach MW, Azoitei ML, Cui J, Pelker JW, Jussif J, Benoit S, Ireland G, Luxenberg D, Askew GR, Milarski KL, Groves C, Brown T, Carito BA, Percival K, Carreno BM, Collins M, Marusic S.

J Neuroimmunol. 2007 Jan;182(1-2):124-34. Epub 2006 Dec 19.


Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis.

McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, Pirhonen J, Kolls JK.

J Immunol. 2005 Jul 1;175(1):404-12.


The B7 family of immune-regulatory ligands.

Collins M, Ling V, Carreno BM.

Genome Biol. 2005;6(6):223. Epub 2005 May 31. Review.


Therapeutic opportunities in the B7/CD28 family of ligands and receptors.

Carreno BM, Carter LL, Collins M.

Curr Opin Pharmacol. 2005 Aug;5(4):424-30. Review.


Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells.

Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M, Shevach EM.

J Immunol. 2004 Oct 15;173(8):5008-20.


Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand.

Madrenas J, Chau LA, Teft WA, Wu PW, Jussif J, Kasaian M, Carreno BM, Ling V.

J Immunol. 2004 May 15;172(10):5948-56.


BTLA: a new inhibitory receptor with a B7-like ligand.

Carreno BM, Collins M.

Trends Immunol. 2003 Oct;24(10):524-7. Review.


TCR subunit specificity of CTLA-4-mediated signaling.

Siu E, Carreno BM, Madrenas J.

J Leukoc Biol. 2003 Dec;74(6):1102-7. Epub 2003 Sep 12.


Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss.

Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, Carreno BM, Collins M.

Genomics. 2003 Sep;82(3):365-77.


Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, Nishimura H, Taylor PA.

J Immunol. 2003 Aug 1;171(3):1272-7.


Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, Khan N, Veldman G, Jacobs KA, Valge-Archer VE, Collins M, Carreno BM.

J Immunol. 2003 Jan 15;170(2):711-8.


Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A.

Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, Collins M, Carreno BM, Madrenas J, Kuchroo VK.

J Immunol. 2002 May 15;168(10):5070-8.


The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

Carreno BM, Collins M.

Annu Rev Immunol. 2002;20:29-53. Epub 2001 Oct 4. Review.


PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.

Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM.

Eur J Immunol. 2002 Mar;32(3):634-43.


PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ.

Nat Immunol. 2001 Mar;2(3):261-8.


Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T.

J Exp Med. 2000 Oct 2;192(7):1027-34.


CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.

Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J.

J Immunol. 2000 Aug 1;165(3):1352-6.


The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation.

Baroja ML, Luxenberg D, Chau T, Ling V, Strathdee CA, Carreno BM, Madrenas J.

J Immunol. 2000 Jan 1;164(1):49-55.


CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction.

Blair PJ, Riley JL, Levine BL, Lee KP, Craighead N, Francomano T, Perfetto SJ, Gray GS, Carreno BM, June CH.

J Immunol. 1998 Jan 1;160(1):12-5.


Are transporter associated with antigen processing (TAP) and tapasin class I MHC chaperones?

Solheim JC, Carreno BM, Hansen TH.

J Immunol. 1997 Jan 15;158(2):541-3.


TAP associates with a unique class I conformation, whereas calnexin associates with multiple class I forms in mouse and man.

Carreno BM, Solheim JC, Harris M, Stroynowski I, Connolly JM, Hansen TH.

J Immunol. 1995 Nov 15;155(10):4726-33.


Characterization of class I MHC folding intermediates and their disparate interactions with peptide and beta 2-microglobulin.

Smith JD, Solheim JC, Carreno BM, Hansen TH.

Mol Immunol. 1995 May;32(7):531-40.


Peptide-induced rescue of serologic epitopes on class I MHC molecules.

Solheim JC, Carreno BM, Myers NB, Lee DR, Hansen TH.

J Immunol. 1995 Feb 1;154(3):1188-97.


Binding of peptides lacking consensus anchor residue alters H-2Ld serologic recognition.

Solheim JC, Carreno BM, Smith JD, Gorka J, Myers NB, Wen Z, Martinko JM, Lee DR, Hansen TH.

J Immunol. 1993 Nov 15;151(10):5387-97.


Supplemental Content

Loading ...
Support Center